Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M, Persson JL, Gudas LJ, Rakha E, Robinson BD, Khani F, Martin LM, Moyer JE, Brownlie J, Madhusudan S, Allegrucci C, James VH, Rutland CS, Fray RG, Ntekim A, de Brot S, Mongan NP, Jeyapalan JN. Harris AE, et al. Among authors: alsaleem m. Front Endocrinol (Lausanne). 2022 Oct 3;13:1006101. doi: 10.3389/fendo.2022.1006101. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36263323 Free PMC article. Review.
Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.
Kurozumi S, Joseph C, Sonbul S, Aleskandarany MA, Pigera M, Alsaleem M, Alsaeed S, Kariri Y, Nolan CC, Diez-Rodriguez M, Johnston S, Mongan NP, Fujii T, Shirabe K, Martin SG, Ellis IO, Green AR, Rakha EA. Kurozumi S, et al. Among authors: alsaleem m. Breast Cancer Res Treat. 2018 Nov;172(1):61-68. doi: 10.1007/s10549-018-4891-y. Epub 2018 Jul 28. Breast Cancer Res Treat. 2018. PMID: 30056565
Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.
Kurozumi S, Joseph C, Raafat S, Sonbul S, Kariri Y, Alsaeed S, Pigera M, Alsaleem M, Nolan CC, Johnston SJ, Aleskandarany MA, Ogden A, Fujii T, Shirabe K, Martin SG, Alshankyty I, Mongan NP, Ellis IO, Green AR, Rakha EA. Kurozumi S, et al. Among authors: alsaleem m. Breast Cancer Res Treat. 2019 Jul;176(1):63-73. doi: 10.1007/s10549-019-05216-w. Epub 2019 Apr 2. Breast Cancer Res Treat. 2019. PMID: 30941650
A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.
Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, Shirabe K, Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA. Kurozumi S, et al. Among authors: alsaleem m. Br J Cancer. 2019 Jun;120(12):1129-1136. doi: 10.1038/s41416-019-0486-6. Epub 2019 May 22. Br J Cancer. 2019. PMID: 31114020 Free PMC article.
Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers.
Ogden A, Bhattarai S, Sahoo B, Mongan NP, Alsaleem M, Green AR, Aleskandarany M, Ellis IO, Pattni S, Li XB, Moreno CS, Krishnamurti U, Janssen EA, Jonsdottir K, Rakha E, Rida P, Aneja R. Ogden A, et al. Among authors: alsaleem m. Sci Rep. 2020 Feb 20;10(1):3009. doi: 10.1038/s41598-020-59514-1. Sci Rep. 2020. PMID: 32080212 Free PMC article.
A novel prognostic two-gene signature for triple negative breast cancer.
Alsaleem MA, Ball G, Toss MS, Raafat S, Aleskandarany M, Joseph C, Ogden A, Bhattarai S, Rida PCG, Khani F, Davis M, Elemento O, Aneja R, Ellis IO, Green A, Mongan NP, Rakha E. Alsaleem MA, et al. Mod Pathol. 2020 Nov;33(11):2208-2220. doi: 10.1038/s41379-020-0563-7. Epub 2020 May 13. Mod Pathol. 2020. PMID: 32404959 Free article.
102 results